Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD).

Mark T. Esser, a pharmaceutical researcher and executive, brings scientific expertise and leadership experience to his new ...

Conduit Pharmaceuticals (CDT) announces the filing of two groundbreaking patents for tapinarof, VTAMA, including a dual active cocrystal, ...